lynparza

Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer

pharmafile | January 16, 2020 | News story | Sales and Marketing |  AstraZeneca, MSD, NHS, NICE, UK, lynparza 

It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured recommendation from NICE  for the treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer in adult patients with a BRCA1 or BRCA2 mutation.

Data supplied in support of the case for the drug’s recommendation demonstrated that Lynparza presented a progression-free survival benefit of 19.1 months, compared to 5.5 months for placebo.

The decision means that Lynparza tablets will now be made available to NHS patients in England and Wales who have previously undergone at least three courses of platinum-based chemotherapy.  

While the therapy meets NICE’s end-of-life criteria and was deemed cost-effective in this group, it does not in patients who have only received two courses. As a result, NICE believes it has the potential to be cost-effective and has asked for further confirmatory data on overall survival benefit.

Advertisement

In the meantime, it has recommended that the drug be made available via the Cancer Drugs Fund in this patient population, which is estimated to be around 1,100.

NICE previously recommended Lynparza in capsule formulation for patients with a BRCA mutation who have previously received at least three courses of platinum-based chemo.

Matt Fellows

Related Content

NHS expands community ear and hearing pathway across 10 ICBs

A new NHS ear and hearing health pathway supported by TympaHealth has been rolled out …

PlaqueTec coronary disease trial reaches 100 patients across eight NHS centres

PlaqueTec’s BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist …

The evidence bar impacting UK medical cannabis access

By Mike Morgan-Giles Private prescribing of cannabis-based medicines in the UK has more than doubled …

The Gateway to Local Adoption Series

Latest content